An interventional study of Patient navigator in Breast Cancer and Cancer of Breast, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Health services research
Among 80 studies in Breast Neoplasms by Washington University School of Medicine — 18 open to participants now, 22 under way, none of them phase 3. Breast Neoplasms · Washington University School of Medicine.
Among the 80 studies in Breast Neoplasms by Washington University School of Medicine, this one is the 9th largest by planned enrollment of the 74 interventional ones, is one of 6 that started in 2026, is one of 26 with no phase, reaches primary completion later than 12 of the 21 other live ones, and was the 78th registered.
14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
This study's planned enrollment of 180 is above the median of 72 across 10,896 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →18 of the 80 studies in Breast Neoplasms by Washington University School of Medicine are open now, in 1 country. Each count lists the studies.
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →80 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 6 started in 2026.
Median enrollment 55 across the 74 interventional studies, 100 across the 6 observational. Of the 53 that completed or were terminated, 22 (42%) have results posted.
Washington University School of Medicine is the lead sponsor of 1,803 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
4 of the studies in Breast Neoplasms by Washington University School of Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04354064Washington University School of MedicineCirculating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors | 2026-12-31 |
| NCT02476786Washington University School of MedicineEndocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | 2027-01-31 |
| NCT00353483Washington University School of MedicineEffect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells | 2027-08-31 |
| NCT05837455Washington University School of MedicineNeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer | 2027-11-30 |
Among the 80 studies in Breast Neoplasms by Washington University School of Medicine, from their registry updates:
This study aims to assess how individual patient social stressors are associated with barriers to care by analyzing a patient navigator system. Patient navigators will connect patients with unmet social needs with community resources.
Eligibility Criteria:
Patients will be connected with a patient navigator following consent. The navigator will ask the patient questions regarding social determinants of health risks including transportation difficulties, financial stability, and housing stability. Patient will receive full social determinants of health (SDOH) screening via iPad at initial consult visit. Based on SDOH screening, if the patient is high risk the patient will be referred to appropriate resources.
Behavioral: Patient navigator
Patient navigator will contact the patient every 3 weeks to check in, assess if patient requires additional resources, connect patient to existing nonprofit and local resources, remind patient of appointments, and ask about barriers to clinic visits.
Percentage of patients with chemotherapy deferrals
Time frame: 6 months
Rate of visit no-shows
Time frame: 6 months
Rate of visit cancellations
Time frame: 6 months
Plan to share: No
Started Oct 2026 (actual). Primary completion is estimated for Oct 2028, 24 months after the start.
Of 2,661 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 24 months is below that.
Counting every sponsor, half of 2,771 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Sep 2026 → Oct 2026, primary completion Sep 2028 → Oct 2028 and completion Sep 2028 → Oct 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington University School of Medicine →